In the registrational clinical trial for patients with NTRK fusion-positive solid tumors, zurletrectinib demonstrated outstanding efficacy and a favorable safety profile. The study results showed an objective response rate (ORR) of 89.1%, a disease control rate (DCR) of 96.4%, and 24-month progression-free survival (PFS) and overall survival (OS) rates of 77.4% and 90.8% respectively. Read More
Source link
Supreme Court hears arguments over birthright citizenship
IE 11 is not supported. For an optimal experience visit our site on another browser. Now Playing Supreme Court hears arguments over birthright citizenship 01:13 UP NEXT Megan Thee Stallion…






